|
1
|
Kitahara CM and Sosa JA: Understanding the
ever-changing incidence of thyroid cancer. Nat Rev Endocrinol.
16:617–618. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Laha D, Nilubol N and Boufraqech M: New
therapies for advanced thyroid cancer. Front Endocrinol (Lausanne).
11(82)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
D'Alessandria C, Braesch-Andersen S, Bejo
K, Reder S, Blechert B, Schwaiger M and Bartolazzi A: Noninvasive
In vivo imaging and biologic characterization of thyroid tumors by
immunoPET targeting of galectin-3. Cancer Res. 76:3583–3592.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
De Rose F, Braeuer M, Braesch-Andersen S,
Otto AM, Steiger K, Reder S, Mall S, Nekolla S, Schwaiger M, Weber
WA, et al: Galectin-3 targeting in thyroid orthotopic tumors opens
new ways to characterize thyroid cancer. J Nucl Med. 60:770–776.
2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cardoso AC, Andrade LN, Bustos SO and
Chammas R: Galectin-3 Determines tumor cell adaptive strategies in
stressed tumor microenvironments. Front Oncol.
6(127)2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gordon-Alonso M, Bruger AM and van der
Bruggen P: Extracellular galectins as controllers of cytokines in
hematological cancer. Blood. 132:484–491. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Johannes L, Jacob R and Leffler H:
Galectins at a glance. J Cell Sci. 131(131)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gordon-Alonso M, Hirsch T, Wildmann C and
van der Bruggen P: Galectin-3 captures interferon-gamma in the
tumor matrix reducing chemokine gradient production and T-cell
tumor infiltration. Nat Commun. 8(793)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Xue H, Liu L, Zhao Z, Zhang Z, Guan Y,
Cheng H, Zhou Y and Tai G: The N-terminal tail coordinates with
carbohydrate recognition domain to mediate galectin-3 induced
apoptosis in T cells. Oncotarget. 8:49824–49838. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Harazono Y, Kho DH, Balan V, Nakajima K,
Hogan V and Raz A: Extracellular galectin-3 programs multidrug
resistance through Na+/K+-ATPase and
P-glycoprotein signaling. Oncotarget. 6:19592–19604.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Nangia-Makker P, Balan V and Raz A:
Regulation of tumor progression by extracellular galectin-3. Cancer
Microenviron. 1:43–51. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gao X, Balan V, Tai G and Raz A:
Galectin-3 induces cell migration via a calcium-sensitive
MAPK/ERK1/2 pathway. Oncotarget. 5:2077–2084. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Elad-Sfadia G, Haklai R, Balan E and Kloog
Y: Galectin-3 augments K-Ras activation and triggers a Ras signal
that attenuates ERK but not phosphoinositide 3-kinase activity. J
Biol Chem. 279:34922–34930. 2004.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Levy R, Grafi-Cohen M, Kraiem Z and Kloog
Y: Galectin-3 promotes chronic activation of K-Ras and
differentiation block in malignant thyroid carcinomas. Mol Cancer
Ther. 9:2208–2219. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bartolazzi A, Sciacchitano S and
D'Alessandria C: Galectin-3: The impact on the clinical management
of patients with thyroid nodules and future perspectives. Int J Mol
Sci. 19(E445)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lavra L, Rinaldo C, Ulivieri A, Luciani E,
Fidanza P, Giacomelli L, Bellotti C, Ricci A, Trovato M, Soddu S,
et al: The loss of the p53 activator HIPK2 is responsible for
galectin-3 overexpression in well differentiated thyroid
carcinomas. PLoS One. 6(e20665)2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kuklinski S and Probstmeier R: Homophilic
binding properties of galectin-3: Involvement of the carbohydrate
recognition domain. J Neurochem. 70:814–823. 1998.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ho MK and Springer TA: Mac-2, a novel
32,000 Mr mouse macrophage subpopulation-specific antigen defined
by monoclonal antibodies. J Immunol. 128:1221–1228. 1982.PubMed/NCBI
|
|
19
|
Pesheva P, Urschel S, Frei K and
Probstmeier R: Murine microglial cells express functionally active
galectin-3 in vitro. J Neurosci Res. 51:49–57. 1998a.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Pesheva P, Kuklinski S, Schmitz B and
Probstmeier R: Galectin-3 promotes neural cell adhesion and neurite
growth. J Neurosci Res. 54:639–654. 1998b.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lobastova L, Kraus D, Glassmann A, Khan D,
Steinhäuser C, Wolff C, Veit N, Winter J and Probstmeier R:
Collective cell migration of thyroid carcinoma cells: A beneficial
ability to override unfavourable substrates. Cell Oncol (Dordr).
40:63–76. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Knibbs RN, Agrwal N, Wang JL and Goldstein
IJ: Carbohydrate-binding protein 35. II. Analysis of the
interaction of the recombinant polypeptide with saccharides. J Biol
Chem. 268:14940–14947. 1993.PubMed/NCBI
|
|
23
|
Fettis MM and Hudalla GA: Engineering
reactive oxygen species-resistant galectin-1 dimers with enhanced
lectin activity. Bioconjug Chem. 29:2489–2496. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cedeno-Laurent F and Dimitroff CJ:
Galectin-1 research in T cell immunity: Past, present and future.
Clin Immunol. 142:107–116. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Anananuchatkul T, Chang IV, Miki T,
Tsutsumi H and Mihara H: Construction of a stapled α-helix peptide
library displayed on phage for the screening of galectin-3-binding
peptide ligands. ACS Omega. 5:5666–5674. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Frigeri LG and Liu FT: Surface expression
of functional IgE binding protein, an endogenous lectin, on mast
cells and macrophages. J Immunol. 148:861–867. 1992.PubMed/NCBI
|
|
27
|
Inohara H and Raz A: Functional evidence
that cell surface galectin-3 mediates homotypic cell adhesion.
Cancer Res. 55:3267–3271. 1995.PubMed/NCBI
|
|
28
|
Zheng J, Lu W, Wang C, Xing Y, Chen X and
Ai Z: Galectin-3 induced by hypoxia promotes cell migration in
thyroid cancer cells. Oncotarget. 8:101475–101488. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wu KL, Kuo CM, Huang EY, Pan HM, Huang CC,
Chen YF, Hsiao CC and Yang KD: Extracellular galectin-3 facilitates
colon cancer cell migration and is related to the epidermal growth
factor receptor. Am J Transl Res. 10:2402–2412. 2018.PubMed/NCBI
|
|
30
|
Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara
I, Yamanaka T, Hirashima M and Liu FT: Human galectin-3 is a novel
chemoattractant for monocytes and macrophages. J Immunol.
165:2156–2164. 2000.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Peplau E, De Rose F, Reder S, Mittelhäuser
M, Scafetta G, Schwaiger M, Weber WA, Bartolazzi A, Skerra A and
D'Alessandria C: Development of a chimeric antigen-binding fragment
directed against human galectin-3 and validation as an
immuno-positron emission tomography tracer for the sensitive in
vivo imaging of thyroid cancer. Thyroid. 30:1314–1326.
2020.PubMed/NCBI View Article : Google Scholar
|
